Two new studies have been published on psoriatic arthritis and reported in stories by Reuters via Medscape News.

The first story, "Nail Dystrophy a Predictor of Psoriatic Arthritis in Psoriasis Patients", states, "Less than 10% of psoriasis patients develop psoriatic arthritis during their lifetime," but that, "clinical predictors of psoriatic arthritis included scalp lesions (hazard ratio 3.89), nail dystrophy (HR 2.93), and intergluteal/perianal lesions (HR 2.35)."

To read the full story, click here.

The second, "Anti-IL-12/23 Monoclonal Antibody Useful for Psoriatic Arthritis", discusses the use of ustekinumab in treating psoriatic arthritis. Ustekinumab is in stage II trials.

"Treatment with ustekinumab, a monoclonal antibody against interleukins 12 and 23, can reduce the signs and symptoms of psoriatic arthritis and is well tolerated," the study states and that there is a need for medications to treat patients in cases when "standard treatments, such as disease-modifying antirheumatic drugs and anti-TNF agents, fail."

To read this story, click here.

STAY INFORMED! Stay up-to-date on all the latest news and information regarding AS and related diseases with our news magazine, Spondylitis Plus. Your subscription comes free with SAA membership, so click here to join today!